Aussie pensioner left to rot in squalid public housing nightmare
The retiree, who wishes to remain anonymous, has been living in his Coogee home since 2016, according to Yahoo News, after suffering a stroke.
But within a year, the mould started its insidious takeover, and his mate and carer, Grace Thomas, has been battling the clueless housing authority ever since.
After a promising start in 2018 – with the resident whisked away to temporary digs while they supposedly tackled the mould – the problem just kept coming back, bigger and uglier than before.
MORE NEWS
'Plywood caskets': Outrage over bizarre $1025 rental
Aussie man locked in $100k battle with council
Where Aus tenants pay the most
It was only when the man's electricity was cut off again, due to 'water in the walls', that Ms Thomas went nuclear on the housing authority.
'There was mould everywhere… it grew insurmountable,' she told Yahoo News.
'He actually placed tarps on the floor and then little rugs on the top, so that he could step out without feeling the squelch underneath his feet whenever he went to get out of bed.
'He was broken, and had given up.'
MORE NEWS: Inside Australia's haunting mall mystery
Supplied images show the horrifying extent of the black mould infestation – growing in the man's carpet, bathroom, kitchen, furniture, and even on his front door.
In October last year, an independent report from a mould specialist at BlueBay Group confirmed what was already glaringly obvious: 'the current environment is not safe for human living'.
Finally, after a hygienist report, the retiree was moved to temporary accommodation by Homes NSW, where he remains today.
In a statement to Yahoo News, Home NSW recognised that the condition of the tenant's home had not met acceptable standards.
The government department is now looking to relocate the resident to 'a more suitable, ground-floor property in the local area' and confirmed he will stay in temporary accommodation until his new unit is ready.
Remaining units in the Coogee complex will also be inspected for mould.
'Homes NSW is committed to providing safe, well-maintained homes that meet tenants' needs,' a government spokesperson said.
How can I prevent mould from growing in my home?
Although mould can be found almost anywhere, it needs moisture and nutrients to grow. The following actions can help prevent mould growth by reducing dampness in the home.
– Maintain proper ventilation: Turn on exhaust fans, particularly when bathing, showering, cooking, doing laundry and drying clothes. Open windows when weather permits, to improve cross ventilation.
– Reduce humidity
– Limit the use of humidifiers.
– Limit the number of fish tanks and indoor plants.
– Limit use of unflued gas heaters
– Control moisture and dampness: Repair all water leaks and plumbing problems, for example, burst water pipes, leaking roof or blocked rain gutter. If water enters your home, completely clean and dry water-damaged carpets and building materials. Discard material that cannot be cleaned and dried completely.
What are possible health problems from contact with mould?
Health effects of mould exposure include a runny or blocked nose, irritation of the eyes and skin, and sometimes wheezing.
For people with asthma, inhaling mould spores may cause an asthma attack.
Very rarely, people may develop a severe mould infection, usually in the lungs – however, it is important to see a doctor if mould related health problems are suspected.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
20 minutes ago
- ABC News
Restless Dance Theatre takes the arts to the end of a hospital bed with The Lensical
Inside a hospital room at the Adelaide Women's and Children's Hospital, the lights are dimmed and voices gentle. A small, smiling figure is tucked in white sheets in a bed at the centre of the room, his parents in chairs by his side. In the low light, the boy's eyes are bright and open wide, watching intently as dancers in white boilersuits quietly enter the room. They bring with them a very curious structure. It's large and about a metre-and-a-half long. There's a face-sized hole at one end, extending out into an octagonal shape at the other — and it's designed to hover over the hospital bed. For the patient, the device blocks from sight the hospital setting, and headphones playing music replace the sound of whirring medical machines. And so the unconventional stage is set for a first-of-its-kind performance, especially designed for long-term patients in hospital. This performance, and the device, is called The Lensical. And it's been years in the making. "The work is about delivering a unique, special experience to people who may not otherwise be able to experience that at that time," choreographer Michelle Heaven says. The work aims to create "something magical" that can shift the space for a patient, "even if it is just for a short period". Bhodi Hudson, a dancer in the performance, describes the Lensical object as like "a road cone or a megaphone, but it's on its side ... and you're looking through it". "It is essentially a ginormous cone where the patient in a hospital bed gets to view it," he says. "It's like a personal viewing experience, like you're watching something on a screen but it's there in reality. It's oddly very surreal yet fascinating when you're seeing it first hand." For around four minutes, performers from Restless Dance Theatre, an acclaimed company made up of dancers with and without disabilities, move in and out of this frame, performing enchanting choreography. In response, the small boy becomes animated, doing wiggly, dancing movements as he sits up in his bed looking through the giant lens. The innovative Lensical concept was devised by Heaven in collaboration with her partner, theatre designer Ben Cobham. They've made a lot of theatre together over the years, and Cobham himself was a long-term patient in hospital when he was a kid. "We [wanted] to do something for kids that are like he was when he was little," Heaven says. "He spent close to a year in hospital and one of the things that brought him relief was to watch the fish in the fish tank, their organic movements. "This was also pre-screens and phones that are very prevalent now, which also provide a form of escape, but we [were] wanting to offer a human interaction and not always be so reliant on screens for distraction … to be immersed in something that's really directly shared between people." They arrived at the idea of a performance located at the end of a patient's bed that could "change the environment for them momentarily". Many stages of development and testing followed until the pair arrived at the uplifting and immersive Lensical project. Initial trials took place at the Royal Children's Hospital in Melbourne, where they learnt about hospital codes and infection control. They did additional trials at Adelaide's Flinders Medical Centre and Women's and Children's Hospital, refining the work to both evoke delight and meet strict hospital protocols. And the choreography came with specific constraints too: the piece needed to be able to be performed in the very narrow space at the end of a hospital bed. "There's not a lot of room and we need to be mindful of staff needing to get past to attend to other patients … so it's a very different environment to consider," Heaven says. "There's a lot of different needs here, and … we really try and gently navigate that and be very respectful of it." Hudson, who is autistic, is used to shows on a stage, and describes performing in the restricted space as "tricky". "You may be a little bit squeezed in … You have to make sure you're at the right tempo all the while making sure you're not smacking your partner in the face. You may also give way to other people who need to get [through]." But the contorting effort is worth it for Hudson, who says the work is "funky … not smelly, [but] fun funky". In the sequence he performs with fellow Restless dancer Sidney Debba, the pair hold cloths and perform choreography based around pretending to clean an invisible window at the end of the Lensical. "It's like a fantasy sequence in a film where someone just dances to music [doing] the most mundane thing, like someone dancing with a broom like it's a partner," Hudson says. Dancers perform two short works, Heaven explains. "One is quite light and fun and literally makes particularly the younger ones giggle … That's really magical. And the other work is quite transporting, you are immersed in something; it's quite special. "We might just bring the hands in for a moment, or something else might come into frame you might not expect … It's very non-threatening and brings your attention to detail and creates a human connection." Across four days at two different hospitals, the troupe moves quietly through different wards, the Lensical rolling into the rooms of patients who are keen to see the visiting spectacle. Heaven says seeing the work properly performed for the first time, as part of Adelaide's DreamBIG Children's Festival, has been a moving experience. At Adelaide Women's and Children's Hospital and Flinders Medical Centre, they performed the short dances to audiences of a wide range of ages, from children between two and 18 years old through to their families — and even staff. "It [was] a moment of relief, like a little reset, people have used that word … and then [they] go on to do what else they have to do that day." Heaven says the main response among patients has been a feeling of calm joy. She's seen some patients moved to tears, "but in a joyful release".
ABC News
an hour ago
- ABC News
Up to 200 women a month to access new Sydney virtual menopause hub
Lucy Bloom experienced flushes of "raging heat" and bursts of anger or sadness when she dealt with perimenopause for about a decade. "My internal furnace would switch on for about 90 seconds, and I felt like my head was going to explode, but I knew it would pass, so I would just sit through it," she said. Ms Bloom, 51, was prescribed hormone replacement therapy (HRT) — a common treatment for menopause that made an "enormous difference" to her quality of life. In March, three medications for menopausal hormone therapy, including HRT, were added to the Pharmaceutical Benefits Scheme. However, women experiencing perimenopause and menopause symptoms can still face lengthy wait times for a clinical appointment. Ms Bloom waited six months for an appointment at the Royal Hospital for Women in Randwick but said she was fortunate to have a GP who prescribed her the right treatment. "The menopause clinic at the women's hospital is brilliant, but you can wait up to a year for an appointment there," she said. "There's that much demand to see a doctor. "If I'd had access to an online menopause hub, it would have closed that gap quickly." The NSW government announced a virtual menopause hub for south-west Sydney on Tuesday. With its home base at Campbelltown Hospital, the online space will serve patients going through complex perimenopause and menopause across Western Sydney, Nepean Blue Mountains, and the Murrumbidgee local health districts. To access support, patients will need to undergo an initial assessment with their GP for a referral in a process covered by Medicare. The South Western Sydney Local Health District expects up to 200 women will access it every month — a number projected to increase gradually over time. Health Minister Ryan Park said the hub was designed to act as a "pathway" to offer further support to women who have tried multiple types of treatment. "This pathway is designed to be for women to be referred into if they are suffering from those complex symptoms, if they have not had any relief, and if they've undertaken care already but haven't been able to get that issue managed," he said. Mr Park described the new hub as the "final piece in the puzzle". "The real focus is not just the hubs and the treatment … it's about the professional development and training, particularly of our GPs and our primary care providers." The virtual service is the fourth menopause hub in the state, with existing locations at St Leonards, Randwick, and Wallsend to the west of Newcastle. It is estimated about 1,000 women will access health services across the four menopause hubs. Gynaecologist Yasmin Tan said the menopause hubs across the state were "a really excellent start". She said there could be a three-to-nine-month wait for some health clinics. "There's a huge demand for these services," she said. "This area of women's health has really been neglected for many years." Dr Tan said having more doctors trained to provide these services would help improve wait times. Menopause symptoms often include mood-related disorders, which Dr Tan said needed to be met with a holistic approach. "You're not just a uterus, you're not just a breast, you're not just your psychiatric health," she said. "You're a whole person and it all interacts with each other. So, we need a team approach for these more complex cases." Dr Tan believes menopause healthcare has "come a long way" in the past two years. "Menopause management is more than treating hot flushes. It's about preserving long term health and wellbeing — physically and mentally," she said.
News.com.au
an hour ago
- News.com.au
ASX biotechs join global race for cell therapy breakthroughs
ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable. By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body. Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases. Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017. While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare. Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%. In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies. Arovella in rare biotech club targeting CAR-iNKT therapies Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally. CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations. T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system. Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient. The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments. While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited. Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells. Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model. Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia. One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients. The company's other key goal is also tackling solid tumours. "The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said. "We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs. "There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector. "That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.' Imugene also aims to crack solid tumours Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours. The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date. Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma. In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies. "We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead. Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system. The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells. The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours. By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour. Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens. The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda). The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer. This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases. Chimeric advances cell therapy assets in solid tumours Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut. Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer. CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours. Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML). "We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead. Prescient advancing cell therapy platforms While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms. OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration. CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour. AdAlta adopts East to West cellular immunotherapy strategy AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets. SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis. The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets. Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years. The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.
